Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design
Galux, a South Korean biotech pioneering AI-driven protein therapeutics discovery, announced that it has signed a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence (AI) in precision protein design for therapeutic development. The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations.
Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design
Galux, a South Korean biotech pioneering AI-driven protein therapeutics design, announced new experimental findings demonstrating that its AI protein design platform, GaluxDesign, can reliably generate high-affinity antibodies from minimal design sets, signaling a meaningful shift in how therapeutic antibodies can be discovered.
